Ipratropium (inhaled, nasal)

An anticholinergic bronchodilator inhaled for COPD and used as a nasal spray for runny nose from year-round rhinitis.

psilodex.org/m/ipratropium · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~1.6–2 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Ipratropium (inhaled, nasal)”, v2026.10.05. psilodex.org/m/ipratropium

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Maintenance treatment of bronchospasm in COPD, including chronic bronchitis and emphysema (inhaled)
Runny nose from allergic and nonallergic year-round rhinitis (nasal spray)

Sources [1][2]

01 Interaction with psilocybin

Not studied with psilocybin; little of it reaches the blood, so whole-body effects adding to psilocybin's may be small.

Detail Ipratropium is anticholinergic (acetylcholine-blocking). As a quaternary amine, it is not readily absorbed into the circulation from the lungs or gut. So whole-body anticholinergic effects that could add to psilocybin's are expected to be small. There are no psilocybin data. Separately, its label notes it may raise eye pressure and cause urinary retention. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~1.6–2 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed (1 possible) · counted on reports

AnticholinergicPossible: Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination.Possible: The source describes the effect as small, seen only in laboratory or animal studies, or theoretical. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Asthma or COPD (provision applies if severe or unstable)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

ATROVENT HFA (ipratropium bromide) inhalation aerosol (Boehringer Ingelheim) · FDA label (DailyMed) — Anticholinergic: 5.4 "ATROVENT HFA is an anticholinergic and its use may increase intraocular pressure." | 5.5 "ATROVENT HFA is an anticholinergic and may cause urinary retention." | 12.3 "Ipratropium bromide is a quaternary amine and hence is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract" | "The half-life of elimination is about 2 hours after inhalation or intravenous administration."
Ipratropium Bromide Nasal Solution 0.03% (Apotex) · FDA label (DailyMed) — Indications: "symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older" | "the terminal half-life of ipratropium was approximately 1.6 hours"

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →